Archive
549 articles, sorted by publication time.
The collaboration again pushes the promise of biomedical AI to the front line of drug discovery; but before the disease target, data sources, and experimental evidence are disclosed, it is more like a research and development starting point that deserves rigorous testing.
UCI Health’s REGEN4HD clinical trial has completed neural stem cell therapy in its first patient, moving an idea long confined to the laboratory and surgical planning into humans; but this is not a declaration of efficacy. It is the starting point for safety, post-implantation cell fate, and long-term follow-up.
A 23-year-old sickle cell patient in Louisiana was described as functionally cured after receiving Casgevy, but the real novelty lies not only in efficacy, but in whether complex cell therapies can be reliably taken up by more regional hospitals.
A new preprint brings the competition in medical AI back to a basic question: a truly useful clinical assistant may not be a tool branded as specialist by origin, but a general-purpose model that can handle knowledge, context, and safety reasoning together.
A study using artificial intelligence to design vaccine antigens is drawing renewed attention; it points to the possibility of preparing in advance for viral mutations, while also reminding readers that early safety signals remain far from becoming public health tools.
This $15 million collaboration is not just another AI drug discovery deal; it brings the question of how human immune data can be translated into testable drug hypotheses onto the decision-making table of a major pharmaceutical company.
The safety signal allows a CBD drug development program to move forward, but for pain patients, the real question is not whether cannabidiol can be tolerated, but whether it can prove stable, quantifiable pain reduction in a rigorous trial.
More durable than mRNA and potentially better suited to short-term protein expression, circular RNA is drawing investors and pharma companies to reimagine gene therapy; but the real hurdle lies not in conceptual novelty, but in delivery, dose control and human evidence.
Rentosertib’s Phase 2a trial moves AI drug development from demonstration platforms into the ward; it is not a declaration of victory, but a more testable starting point.
If an early-stage drug can truly make muscle grow back, its significance would extend beyond a single disease; but public details remain limited, and the real question is whether this muscle-building signal can translate into measurable, sustained functional improvement.
The immuno-inflammatory field remains one of the areas where capital is most willing to place bets; Bionyra’s launch shows that investors believe next-generation biologics still have room to reshape efficacy, dosing, and patient stratification.
An industry signal at BIO 2026 has pushed AI drug discovery from algorithm demonstrations toward clinical evidence; but behind a news lead with limited data, the real question remains whether candidate drugs can pass human trials and regulatory review.